An overview on the treatment of postmenopausal osteoporosis

Maeda, Sérgio Setsuo; Lazaretti-Castro, Marise

doi:10.1590/0004-2730000003039

Cited by 67 publications

(99 citation statements)

References 57 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…-Anabolički lekovi koji povećavaju formiranje kostiteriparatide -Lekovi koji istovremeno imaju i antiresorptivni i anabolički efekat-stroncijum ranelat 20,21 Bisfosfonati inhibiraju aktivnost osteoklasta i redukuju vertebralne i nevertebralne frakture. Alendronat i risendronat se koriste i u terapiji osteoporoze kod muškaraca i osteoporoze indukovane glukokortikoidima i uzimaju se sa punom čašom vode 30-60 minuta pre prvog obroka.…”

Section: Seminar Za Lekare Praktičare / Seminar For Practicing Physicianunclassified

“…21 Raloksifen je selektivni estrogen receptorni modulator. Ima aktivnost estrogenskog agoniste na kostima i lipidima i estrogenskog antagoniste u dojci i uterusu.…”

unclassified

“…Upotreba bazedoksifena povezana je sa vazomotornim simptomima, grčevima u nogama i tromboembolijom. 21 Denosumab je RANKL inhibitor, odnosno humano monoklonsko antitelo koje se koristi u terapiji osteoporoze kod postmenopauzalnih žena sa visokim rizikom od nastanka fraktura kao i za povećanje koštane mase kod muškaraca obolelih od osteoporoze. Smanjuje nivo kalcijuma u krvi te može izazvati spazme, trzaje i grčeve u mišićima.…”

unclassified

“…Dugotrajna primena stroncijum ranelata je bezbedna i povezana je sa održivim porastom BMD. 21 Praćenje terapije Neophodno je vršiti procenu terapije, merenjem BMD-a prvi put nakon 24 meseca. Češće testiranje se preporučuje kada dolazi do ubrzanog gubitka kosti kao što je to slučaj sa hroničnom primenom glukokortikoida.…”

unclassified

See 3 more Smart Citations

Osteoporosis in primary health care: A silent epidemics

Vukosavljević¹,

Šimić²,

Vukosavljević³

et al. 2014

PONS

View full text Add to dashboard Cite

1. Služba opšte medicine, Dom zdravlja, Jagodina 2. Služba opšte medicine, Dom zdravlja, Rekovac 3. Visoka medicinska škola strukovnih studija, Ćuprija 4. Služba za kućno i palijativno lečenje i negu, Dom zdravlja, Jagodina RECEIVED 29. 07.201407. . ACCEPTED 11.11.2014. SAŽETAKOsteoporoza je sistemska skeletna bolest koja se karakteriše niskom koštanom masom i pogoršanjem koštane mikoroarhitekture, što dovodi do povećane koštane fragilnosti i za posledicu ima povećani rizik od frakture. Procenjeno je da 22 miliona žena i 5,5 miliona muškaraca u Evropskoj uniji ima osteoporozu. Osteoporoza je asimptomatska bolest, simptomi su znak uznapredovalog oboljenja i posledica nastalih fraktura. Dijagnoza osteoporoze se postavlja na osnovu merenja mineralne koštane gustine (BMD) metodom dvostruke apsorpcije X zraka (DEXA), na lumbalnoj kičmi i na proksimalnom femuru. BMD se opisuje kao T skor i Z skor. T skor predstavlja odstupanje BMD pacijenta od srednje vrednosti BMD za odgovarajući pol i konstituciju, osobe 20-30 godina starosti,, izraženo u standardnim devijacijama (SD) . Osteoporoza postoji kada je BMD 2,5 SD ili više, ispod prosečne vrednosti za mlade zdrave žene (T skor < -2,5 SD). .Skrining vrši kod žena starijih od 65. godina i muškaraca starijih od 70. godina, zatim kod starijih od 50. godina sa frakturom na minimalnu traumu, kao i kod odabranih postmenopauzalnih žena i muškaraca sa faktorima rizika za nastanak preloma. Osteoporoza se može prevenirati i lečiti. Prevencija obuhvata sprečavanje padova, adekvatan dnevni unos kalcijuma i vitamin D. U tretmanu osteoporoze koriste se sledeće kategorije medikamenata: antiresorptivni lekovi koji usporavaju gubitak kosti-bisfosfonati, kalcitonin, denosumab, estrogen i selektivni modulatori estrogenskih receptora (SREM), anabolički lekovi koji povećavaju formiranje kosti-teriparatide kao i lekovi koji istovremeno imaju i antiresorptivni i anabolički efekat-stroncijum ranelat. . Neophodno je vršiti procenu terapije, merenjem BMD-a prvi put nakon 24 meseca Ključne reči: osteoporoza, mineralna koštana gustina, T skor, faktori rizika, prevencija, lečenje ABSTRACTOsteoporosis is a systemic skeletal disease characterized by low bone mass and deterioration of bone microarchitecture, which leads to bone fragility and resulting in an increased risk of fractures. It is estimated that 22 million women and 5.5 million men in the European Union have osteoporosis. Osteoporosis is asymptomatic disease, the symptoms are a sign of advanced disease and the consequences of fractures. The diagnosis of osteoporosis is based on the measurement of bone mineral density (BMD) using dual X-ray absorption (DEXA) at the lumbar spine and proximal femur. BMD is described as a T score and the Z score. T score represents the deviation of BMD from the mean BMD of the appropriate for gender and constitution, in persons 20-30 years of age, expressed in standard deviations (SD). Osteoporosis occurs when the BMD is -2.5 SD or more below the average value for young healthy women (T score <-2.5 SD). Skrining ...

show abstract

Section: Seminar Za Lekare Praktičare / Seminar For Practicing Physicianunclassified

“…21 Raloksifen je selektivni estrogen receptorni modulator. Ima aktivnost estrogenskog agoniste na kostima i lipidima i estrogenskog antagoniste u dojci i uterusu.…”

unclassified

See 2 more Smart Citations

Osteoporosis in primary health care: A silent epidemics

Vukosavljević¹,

Šimić²,

Vukosavljević³

et al. 2014

PONS

View full text Add to dashboard Cite

show abstract

“…Controlled trials in post-menopausal women have been considered physical exercise along with medication and diet one of the three cornerstones of osteoporosis (10,11). By other hand, there are different accepted diagnostic criteria to identify osteoporosis than may partly explain the variability of prevalence (12); also the incidence of physical exercise to induce changes in bone metabolism is determined for the duration, intensity and type of exercises (9).…”

Section: Introductionmentioning

confidence: 99%

Effect of three months of periodized hydrogymnastics exercise program on urinary concentration of deoxypyridinoline in older women

Martínez

Hall-López

Ávila

et al. 2015

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Objective: To determine the effect of three months of periodized hydrogymnastics exercise program on urinary concentration of deoxypyridinoline in older women. Subjects and methods: Twenty-six subjects were randomly assigned in two, intervention group (n = 16) and control group (n = 10). The intervention group followed 12-week of periodized hydrogymnastics training program five times a week, 50 minutes of water exercise with work heart rate reserve of 40-50% (1-6 th week) increasing the load to 50-60% (7-12 th week); the control group was not involved in exercise and remained sedentary. The urinary concentration of deoxypyridinoline was evaluated by high resolution liquid chromatography using the reactive immulite pyrilinks-D siemens medical solutions, pretest at the baseline and at the end post-test of the 12-week of water-exercise. As statistical analyses mixed 2 x 2 ANOVA was used, also percentage changes (Δ %) was calculated. Results: The results did not show significant improvement (p < 0.05) comparing the interaction intergroup and the measurements of urinary concentration of deoxypyridinoline (p = 0.504), percentage change (Δ %) showed positive improvements in the experimental group of -13.7 (nM/mMcreatine) in comparison with -7.1 (nM/mMcreatine) from the control group. Conclusion: The present study involves periodization increasing the load heart rate reserve of hydrogymnastics exercise in order to produce grater adaptations, but the results showed than is not possible to infer that hydrogymnastics is effective in increase urinary concentration of deoxypyridinoline in older women, will be appropriated in the future more studies to better clarify the possibilities of improvements between hydrogymnastics and urinary concentration of deoxypyridinoline. Arch Endocrinol Metab. 2015;59(6):523-7

show abstract